Why the study?
Do plasma levels of beta-thromboglobulin and platelet factor 4 correlate with cancer disease stage and change with intravenous chemotherapy?
Population
20 patients with cancer, with no evidence of thromboembolism or impaired renal function, and not taking…
Comparison
Intravenous administration of various cytotoxic… vs Patients with inactive disease vs. patients with…
Design
Cohort
Follow-up
Immediate (for chemotherapy effect)
Authors
Loading...
Elevated beta-thromboglobulin in active cancer may indicate platelet activation contributing to thromboembolism risk unaffected immediately by chemotherapy; hypothesis-generating for targeted interventions.
Do plasma levels of beta-thromboglobulin and platelet factor 4 correlate with cancer disease stage and change with intravenous chemotherapy?
Patients with clinically active cancer exhibit elevated levels of beta-thromboglobulin, suggesting ongoing in vivo platelet activation that may contribute to increased thromboembolism risk, which is not immediately altered by intravenous chemotherapy.
Hamid Al‐Mondhiry (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: